Akira Morimoto1, Yukiko Oh2, Sachie Nakamura2, Yoko Shioda3, Tomomi Hayase2, Toshihiko Imamura4, Kazuko Kudo5, Shinsaku Imashuku6. 1. Department of Pediatrics, Jichi Medical University, School of Medicine, Shimotsuke, Japan. Electronic address: akira@jichi.ac.jp. 2. Department of Pediatrics, Jichi Medical University, School of Medicine, Shimotsuke, Japan. 3. Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan. 4. Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan. 5. Department of Pediatrics, Fujita Health University, Toyoake, Japan. 6. Division of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji, Japan.
Abstract
OBJECTIVE: Langerhans cell histiocytosis (LCH) is characterized by immature dendritic cell proliferation, infiltration of LCH lesions by various inflammatory cells, and a lesional cytokine storm. It is classified into three groups on the basis of disease extent, namely, multisystem with risk-organ involvement (MS+), multisystem without risk-organ involvement (MS-), and single-system (SS) disease. We comprehensively analyzed whether serum levels of cytokines/chemokines reflect the disease extent. METHODS: Serum samples from 52 children with LCH (eight, 25, and 19 with MS+, MS-, and SS, respectively) and 34 control children were analyzed quantitatively for 48 humoral factors. DNA samples extracted from biopsied LCH lesions from 12 patients were tested for BRAF V600E status. RESULTS: The LCH patients had significantly higher serum levels of IL-1Ra, IL-3, IL-6, IL-8, IL-9, IL-10, IL12, IL-13, IL-15, IL-17, IL-18, TNF-α, G-CSF, M-CSF, MIF, HGF, VEGF, CCL2, CCL3, CCL7, CXCL1, and CXCL9 than the controls by univariate analysis. Of these IL-9, IL-15 and MIF were significant by multivariate analysis; but not differed between MS and SS diseases. MS disease associated with significantly higher IL-2R, IL-3, IL-8, IL-18, M-CSF, HGF, CCL2, CXCL1, and CXCL9 levels than SS disease by univariate analysis. Of these, CCL2 and M-CSF were significant by multivariate analysis. IL-18 levels were significantly higher in MS+ disease than MS- disease. The LCH patients with BRAF V600E mutation had higher serum levels of CCL7. CONCLUSION: Numerous inflammatory cytokines and chemokines play a role in LCH. Of those, more specific ones reflect the disease extent (MS vs. SS and MS+ vs. MS-) or the BRAF V600E mutation status. It is thought that the most responsible cytokines and chemokines involved in the poor outcome may become future candidate therapeutic targets in LCH.
OBJECTIVE: Langerhans cell histiocytosis (LCH) is characterized by immature dendritic cell proliferation, infiltration of LCH lesions by various inflammatory cells, and a lesional cytokine storm. It is classified into three groups on the basis of disease extent, namely, multisystem with risk-organ involvement (MS+), multisystem without risk-organ involvement (MS-), and single-system (SS) disease. We comprehensively analyzed whether serum levels of cytokines/chemokines reflect the disease extent. METHODS: Serum samples from 52 children with LCH (eight, 25, and 19 with MS+, MS-, and SS, respectively) and 34 control children were analyzed quantitatively for 48 humoral factors. DNA samples extracted from biopsied LCH lesions from 12 patients were tested for BRAFV600E status. RESULTS: The LCH patients had significantly higher serum levels of IL-1Ra, IL-3, IL-6, IL-8, IL-9, IL-10, IL12, IL-13, IL-15, IL-17, IL-18, TNF-α, G-CSF, M-CSF, MIF, HGF, VEGF, CCL2, CCL3, CCL7, CXCL1, and CXCL9 than the controls by univariate analysis. Of these IL-9, IL-15 and MIF were significant by multivariate analysis; but not differed between MS and SS diseases. MS disease associated with significantly higher IL-2R, IL-3, IL-8, IL-18, M-CSF, HGF, CCL2, CXCL1, and CXCL9 levels than SS disease by univariate analysis. Of these, CCL2 and M-CSF were significant by multivariate analysis. IL-18 levels were significantly higher in MS+ disease than MS- disease. The LCH patients with BRAFV600E mutation had higher serum levels of CCL7. CONCLUSION: Numerous inflammatory cytokines and chemokines play a role in LCH. Of those, more specific ones reflect the disease extent (MS vs. SS and MS+ vs. MS-) or the BRAFV600E mutation status. It is thought that the most responsible cytokines and chemokines involved in the poor outcome may become future candidate therapeutic targets in LCH.
Authors: Deepak Chellapandian; Melissa R Hines; Rui Zhang; Michael Jeng; Cor van den Bos; Vicente Santa-María López; Kai Lehmberg; Elena Sieni; Yini Wang; Taizo Nakano; James A Williams; Nicholas J Fustino; Itziar Astigarraga; Ira J Dunkel; Oussama Abla; Astrid G S van Halteren; Deqing Pei; Cheng Cheng; Sheila Weitzman; Lillian Sung; Kim E Nichols Journal: Cancer Date: 2018-12-06 Impact factor: 6.860
Authors: Eli L Diamond; Anne S Reiner; Justin J Buthorn; Elyse Shuk; Allison J Applebaum; David M Hyman; Omar Abdel-Wahab; Raajit Rampal; Filip Janku; Kathleen Brewer; Jean Campbell; Jun J Mao; Thomas M Atkinson; Katherine S Panageas Journal: Blood Adv Date: 2019-04-09
Authors: Huan Liu; Andrew R Osterburg; Jennifer Flury; Zulma Swank; Dennis W McGraw; Nishant Gupta; Kathryn A Wikenheiser-Brokamp; Ashish Kumar; Abdellatif Tazi; Yoshikazu Inoue; Masaki Hirose; Francis X McCormack; Michael T Borchers Journal: JCI Insight Date: 2020-02-27
Authors: Jenée Mitchell; Egle Kvedaraite; Tatiana von Bahr Greenwood; Jan-Inge Henter; Daniel G Pellicci; Stuart P Berzins; George Kannourakis Journal: Sci Rep Date: 2018-11-07 Impact factor: 4.379